June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Several Tear Protein Levels Of Breast Cancer Patients Differ from Healthy Participants: A Microarray Study
Author Affiliations & Notes
  • Ksenia Keller
    Experimental Ophthalmology, University Medical Center, Mainz, Germany
    Gynecology and Obstetrics, University Medical Center, Mainz, Germany
  • Julia Pieter
    Gynecology and Obstetrics, University Medical Center, Mainz, Germany
  • Daniel Boehm
    Gynecology and Obstetrics, University Medical Center, Mainz, Germany
  • Norbert Pfeiffer
    Ophthalmology, University Medical Center, Mainz, Germany
  • Franz Grus
    Experimental Ophthalmology, University Medical Center, Mainz, Germany
  • Footnotes
    Commercial Relationships Ksenia Keller, None; Julia Pieter, None; Daniel Boehm, None; Norbert Pfeiffer, Sensimed AG (F), Sensimed AG (R), MSD (F), MSD (R), Alcon (F), Allergan (F), Novartis (F), Novartis (R), Bayer (F), Heidelberg Engineering (F), Bausch&Lomb (F), Boehringer-Ingelheim (F), Carl Zeiss Meditech (F), Chibret (F), Nidek (F), Pfizer (F), Santen (F), Santen (R), Topcon (F), Ivantis Inc (F), Ivantis Inc (R); Franz Grus, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 929. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ksenia Keller, Julia Pieter, Daniel Boehm, Norbert Pfeiffer, Franz Grus; Several Tear Protein Levels Of Breast Cancer Patients Differ from Healthy Participants: A Microarray Study. Invest. Ophthalmol. Vis. Sci. 2013;54(15):929.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Currently no molecular biomarkers for early detection of breast cancer (BC) are available. The explorations of cancer proteome revealed several new findings according significant level changes of proteins. Even in the distant body fluids like tears we reported over 20 de- or increased proteins in pooled BC and healthy (CTRL) samples in our previous study. Here we report our additional study regarding individual tear protein profiling using high sensitive antibody-microarray plattform

Methods: Tear fluid was obtained from 38 women, whereas 19 of them were diagnosed with primary non-metastasized BC, with the help of Schirmer test. Tear proteins were eluted overnight with 0.1% n-dodecyl-beta-D-maltoside. Proteins were precipitated and their concentration was determined. 5 µg of labeled proteins from each participant were incubated on microarrays with antibodies against complement proteins, other immune components and high abundant tear proteins. After signal visualization a semi-quantitative comparison of protein levels was performed

Results: We detected several significantly different distributed proteins in BC and CTRL groups. For example, the interleukins IL2 and IL1beta were decreased in BC samples (p=0.025 and p=0.017, respectively). Furthermore we used the artificial neuronal networks to test the discrimination ability of the putative biomarkers. Thus the best combination of biomarkers revealed the sensitivity of 89% and specificity of 100%. An area under the curve of 0.91 was achieved

Conclusions: This pilot study provides more findings to our previous tear protein profiling investigations. Obviously also in other body fluids besides serum and tumor microenvironment several protein deregulations occur leading perhaps to changed signal cascades and aberrant reactions. This study also shows the immediate involvement of immune system, whereas its component levels are changed in comparison to CTRL subjects. Further explorations are ongoing for the verifying the results in a larger study population for establishment of putative BC biomarkers

Keywords: 624 oncology • 663 proteomics  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×